Gan & Lee Pharmaceuticals (603087.SH): Investigational Drug GLR1075 Injection Receives Clinical Trial Approval

Gan & Lee Pharmaceuticals (603087.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") regarding its investigational drug GLR1075 Injection. Upon review, the clinical trial application for GLR1075 Injection, accepted on July 3, 2026, complies with the relevant requirements for drug registration, and the product is approved to conduct clinical trials for cirrhosis with ascites and hypoalbuminemia. GLR1075 Injection is a recombinant human albumin preparation independently developed by Gan & Lee Pharmaceuticals, belonging to the category of humanized recombinant protein drugs. Its active ingredient, recombinant human albumin, has the same amino acid sequence and similar spatial conformation as natural human serum albumin, and can exert the core physiological functions of albumin, including correcting colloid osmotic pressure imbalance and improving the pathological microenvironment.